-
2
-
-
0029082311
-
The insulin-like growth factor system and the coupling of formation to resorption
-
Hayden JM, Mohan S, Baylink DJ. The insulin-like growth factor system and the coupling of formation to resorption. Bone 1995;17 2 Suppl:93S-8S.
-
(1995)
Bone
, vol.17
, Issue.2 SUPPL.
-
-
Hayden, J.M.1
Mohan, S.2
Baylink, D.J.3
-
3
-
-
0026613738
-
Vitamin D3 and calcium to prevent hip fractures in the elderly women
-
Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. New England Journal of Medicine 1992;327:1637-42.
-
(1992)
New England Journal of Medicine
, vol.327
, pp. 1637-1642
-
-
Chapuy, M.C.1
Arlot, M.E.2
Duboeuf, F.3
Brun, J.4
Crouzet, B.5
Arnaud, S.6
-
4
-
-
12244253338
-
Effects of vitamin D and calcium supplementation on falls: A randomized controlled trial
-
Bischoff HA, Stahelin HB, Dick W, Akos R, Knecht M, Salis C, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. Journal of Bone and Mineral Research 2003;18:343-51.
-
(2003)
Journal of Bone and Mineral Research
, vol.18
, pp. 343-351
-
-
Bischoff, H.A.1
Stahelin, H.B.2
Dick, W.3
Akos, R.4
Knecht, M.5
Salis, C.6
-
5
-
-
0037374270
-
Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial
-
Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469.
-
(2003)
BMJ
, vol.326
, pp. 469
-
-
Trivedi, D.P.1
Doll, R.2
Khaw, K.T.3
-
7
-
-
0032583492
-
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
-
Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
-
(1998)
JAMA
, vol.280
, pp. 2077-2082
-
-
Cummings, S.R.1
Black, D.M.2
Thompson, D.E.3
Applegate, W.B.4
Barrett-Connor, E.5
Musliner, T.A.6
-
8
-
-
0004851872
-
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
-
Fracture Intervention Trial Research Group
-
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;48:1535-41.
-
(1996)
Lancet
, vol.48
, pp. 1535-1541
-
-
Black, D.M.1
Cummings, S.R.2
Karpf, D.B.3
Cauley, J.A.4
Thompson, D.E.5
Nevitt, M.C.6
-
9
-
-
0033552255
-
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
-
Vertebral Efficacy With Risedronate Therapy (VERT) Study Group
-
Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.
-
(1999)
JAMA
, vol.282
, pp. 1344-1352
-
-
Harris, S.T.1
Watts, N.B.2
Genant, H.K.3
McKeever, C.D.4
Hangartner, T.5
Keller, M.6
-
10
-
-
12944291524
-
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
-
Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
-
Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporosis International 2000;11:83-91.
-
(2000)
Osteoporosis International
, vol.11
, pp. 83-91
-
-
Reginster, J.1
Minne, H.W.2
Sorensen, O.H.3
Hooper, M.4
Roux, C.5
Brandi, M.L.6
-
11
-
-
0035253489
-
Effect of risedronate on the risk of hip fracture in elderly women
-
Hip Intervention Program Study Group
-
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. New England Journal of Medicine 2001;344:333-40.
-
(2001)
New England Journal of Medicine
, vol.344
, pp. 333-340
-
-
McClung, M.R.1
Geusens, P.2
Miller, P.D.3
Zippel, H.4
Bensen, W.G.5
Roux, C.6
-
12
-
-
0036690206
-
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis
-
Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcified Tissue International 2002;71:103-11.
-
(2002)
Calcified Tissue International
, vol.71
, pp. 103-111
-
-
Brown, J.P.1
Kendler, D.L.2
McClung, M.R.3
Emkey, R.D.4
Adachi, J.D.5
Bolognese, M.A.6
-
13
-
-
0034097152
-
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
-
Alendronate Once-Weekly Study Group 15
-
Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group 15. Aging (Milano) 2000;12:1-12.
-
(2000)
Aging (Milano)
, vol.12
, pp. 1-12
-
-
Schnitzer, T.1
Bone, H.G.2
Crepaldi, G.3
Adami, S.4
McClung, M.5
Kiel, D.6
-
14
-
-
0141533811
-
Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis
-
Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. American Journal of Medicine 1997;103:298-307.
-
(1997)
American Journal of Medicine
, vol.103
, pp. 298-307
-
-
Thiebaud, D.1
Burckhardt, P.2
Kriegbaum, H.3
Huss, H.4
Mulder, H.5
Juttmann, J.R.6
-
15
-
-
0037186926
-
Intravenous zoledronic acid in postmenopausal women with low bone mineral density
-
Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine 2002;346:653-61.
-
(2002)
New England Journal of Medicine
, vol.346
, pp. 653-661
-
-
Reid, I.R.1
Brown, J.P.2
Burckhardt, P.3
Horowitz, Z.4
Richardson, P.5
Trechsel, U.6
-
16
-
-
0033829969
-
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Groericanup
-
Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Groericanup. American Journal of Medicine 2000;109:267-76.
-
(2000)
American Journal of Medicine
, vol.109
, pp. 267-276
-
-
Chesnut C.H. III1
Silverman, S.2
Andriano, K.3
Genant, H.4
Gimona, A.5
Harris, S.6
-
17
-
-
0026333422
-
Synthetic human calcitonin in postmenopausal osteoporosis: A placebo-controlled, double-blind study
-
Ljunghall S, Gardsell P, Johnell O, Larsson K, Lindh E, Obrant K, et al. Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study. Calcified Tissue International 1991;49:17-9.
-
(1991)
Calcified Tissue International
, vol.49
, pp. 17-19
-
-
Ljunghall, S.1
Gardsell, P.2
Johnell, O.3
Larsson, K.4
Lindh, E.5
Obrant, K.6
-
18
-
-
0033581212
-
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
-
Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
-
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45.
-
(1999)
JAMA
, vol.282
, pp. 637-645
-
-
Ettinger, B.1
Black, D.M.2
Mitlak, B.H.3
Knickerbocker, R.K.4
Nickelsen, T.5
Genant, H.K.6
-
19
-
-
0035120523
-
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial. Multiple outcomes of raloxifene evaluation
-
Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Research and Treatment 2001;65:125-34.
-
(2001)
Breast Cancer Research and Treatment
, vol.65
, pp. 125-134
-
-
Cauley, J.A.1
Norton, L.2
Lippman, M.E.3
Eckert, S.4
Krueger, K.A.5
Purdie, D.W.6
-
20
-
-
0037138787
-
Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial
-
Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.
-
(2002)
JAMA
, vol.287
, pp. 847-857
-
-
Barrett-Connor, E.1
Grady, D.2
Sashegyi, A.3
Anderson, P.W.4
Cox, D.A.5
Hoszowski, K.6
-
21
-
-
0037125379
-
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
-
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
-
(2002)
JAMA
, vol.288
, pp. 321-333
-
-
Rossouw, J.E.1
Anderson, G.L.2
Prentice, R.L.3
LaCroix, A.Z.4
Kooperberg, C.5
Stefanick, M.L.6
-
22
-
-
0032972664
-
Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: A two-year randomised controlled trial
-
Beardsworth SA, Kearney CE, Purdie DW. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial. British Journal of Obstetrics and Gynaecology 1999;106:678-83.
-
(1999)
British Journal of Obstetrics and Gynaecology
, vol.106
, pp. 678-683
-
-
Beardsworth, S.A.1
Kearney, C.E.2
Purdie, D.W.3
-
23
-
-
0012953649
-
Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomized, placebo-controlled study
-
Berning B, Kuijk CV, Kuiper JW, Bennink HJ, Kicovic PM, Fauser BC. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone 1996;19:395-9.
-
(1996)
Bone
, vol.19
, pp. 395-399
-
-
Berning, B.1
Kuijk, C.V.2
Kuiper, J.W.3
Bennink, H.J.4
Kicovic, P.M.5
Fauser, B.C.6
-
24
-
-
0036123617
-
Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss
-
Roux C, Pelissier C, Fechtenbaum J, Loiseau-Peres S, Benhamou CL. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporosis International 2002;13:241-8.
-
(2002)
Osteoporosis International
, vol.13
, pp. 241-248
-
-
Roux, C.1
Pelissier, C.2
Fechtenbaum, J.3
Loiseau-Peres, S.4
Benhamou, C.L.5
-
26
-
-
0029127973
-
The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength - Assessed in a sexually mature, ovariectomized rat model
-
Mosekilde L, Danielsen CC, Sogaard CH, McOsker JE, Wronski TJ. The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength - assessed in a sexually mature, ovariectomized rat model. Bone 1995;16:223-30.
-
(1995)
Bone
, vol.16
, pp. 223-230
-
-
Mosekilde, L.1
Danielsen, C.C.2
Sogaard, C.H.3
McOsker, J.E.4
Wronski, T.J.5
-
27
-
-
0002693609
-
Effects of LY333334 (Recombinant parathyroid hormone (1-34)) on cortical bone strength indices as assessed by peripheral quantitative computed tomography
-
Program and abstracts of the 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain
-
Zanchetta JR, Bogado C, Ferretti JL, Wang O, Sato M, Gaich GA. Effects of LY333334 (Recombinant parathyroid hormone (1-34)) on cortical bone strength indices as assessed by peripheral quantitative computed tomography. Program and abstracts of the 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone 2001;28 Suppl:S86.
-
(2001)
Bone
, vol.28
, Issue.SUPPL.
-
-
Zanchetta, J.R.1
Bogado, C.2
Ferretti, J.L.3
Wang, O.4
Sato, M.5
Gaich, G.A.6
-
28
-
-
0035837553
-
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
-
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine 2001;344:1434-41.
-
(2001)
New England Journal of Medicine
, vol.344
, pp. 1434-1441
-
-
Neer, R.M.1
Arnaud, C.D.2
Zanchetta, J.R.3
Prince, R.4
Gaich, G.A.5
Reginster, J.Y.6
-
29
-
-
0030804947
-
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
-
Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5.
-
(1997)
Lancet
, vol.350
, pp. 550-555
-
-
Lindsay, R.1
Nieves, J.2
Formica, C.3
Henneman, E.4
Woelfert, L.5
Shen, V.6
-
30
-
-
0034458020
-
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
-
Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. Journal of Clinical Endocrinology and Metabolism 2000;85:2129-34.
-
(2000)
Journal of Clinical Endocrinology and Metabolism
, vol.85
, pp. 2129-2134
-
-
Rittmaster, R.S.1
Bolognese, M.2
Ettinger, M.P.3
Hanley, D.A.4
Hodsman, A.B.5
Kendler, D.L.6
-
31
-
-
18644374464
-
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
-
Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. Journal of Clinical Endocrinology and Metabolism 2002;87:4528-35.
-
(2002)
Journal of Clinical Endocrinology and Metabolism
, vol.87
, pp. 4528-4535
-
-
Body, J.J.1
Gaich, G.A.2
Scheele, W.H.3
Kulkarni, P.M.4
Miller, P.D.5
Peretz, A.6
-
32
-
-
0027316220
-
An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats
-
Marie PJ, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. Journal of Bone and Mineral Research 1993;8:607-15.
-
(1993)
Journal of Bone and Mineral Research
, vol.8
, pp. 607-615
-
-
Marie, P.J.1
Hott, M.2
Modrowski, D.3
De Pollak, C.4
Guillemain, J.5
Deloffre, P.6
-
33
-
-
0000848891
-
The strontium salt S12911 inhibits bone resorption in mouse calvaria and isolated rat osteoclast cultures
-
Su Y, Bonet J, Deloffre P, Tsouderos Y, Baron R. The strontium salt S12911 inhibits bone resorption in mouse calvaria and isolated rat osteoclast cultures. Journal of Bone and Mineral Research 1992;17 Suppl 1:188.
-
(1992)
Journal of Bone and Mineral Research
, vol.17
, Issue.SUPPL. 1
, pp. 188
-
-
Su, Y.1
Bonet, J.2
Deloffre, P.3
Tsouderos, Y.4
Baron, R.5
-
34
-
-
0029812110
-
Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration
-
Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. Journal of Bone and Mineral Research 1996;11:1302-11.
-
(1996)
Journal of Bone and Mineral Research
, vol.11
, pp. 1302-1311
-
-
Boivin, G.1
Deloffre, P.2
Perrat, B.3
Panczer, G.4
Boudeulle, M.5
Mauras, Y.6
-
35
-
-
18344379873
-
Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis - A 2-year randomized placebo controlled trial
-
Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. Journal of Clinical Endocrinology and Metabolism 2002;87:2060-6.
-
(2002)
Journal of Clinical Endocrinology and Metabolism
, vol.87
, pp. 2060-2066
-
-
Meunier, P.J.1
Slosman, D.O.2
Delmas, P.D.3
Sebert, J.L.4
Brandi, M.L.5
Albanese, C.6
-
36
-
-
0035139584
-
The effect of a single dose of osteoprotegerin in postmenopausal women
-
Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. Journal of Bone and Mineral Research 2001;16:348-60.
-
(2001)
Journal of Bone and Mineral Research
, vol.16
, pp. 348-360
-
-
Bekker, P.J.1
Holloway, D.2
Nakanishi, A.3
Arrighi, M.4
Leese, P.T.5
Dunstan, C.R.6
-
37
-
-
15844422855
-
Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts
-
Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. Journal of Biological Chemistry 1996;271:12511-6.
-
(1996)
Journal of Biological Chemistry
, vol.271
, pp. 12511-12516
-
-
Drake, F.H.1
Dodds, R.A.2
James, I.E.3
Connor, J.R.4
Debouck, C.5
Richardson, S.6
-
38
-
-
0029809357
-
Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency
-
Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236-8.
-
(1996)
Science
, vol.273
, pp. 1236-1238
-
-
Gelb, B.D.1
Shi, G.P.2
Chapman, H.A.3
Desnick, R.J.4
-
39
-
-
4243893620
-
Effects of the TNF-alfa antibody imfliximab on serum markers of bone turnover and mineral metabolism in patients with rheumatoid arthritis
-
Dimai HP, Müller T, Eder S, Hermann J. Effects of the TNF-alfa antibody imfliximab on serum markers of bone turnover and mineral metabolism in patients with rheumatoid arthritis. Bone 2001;28:S179.
-
(2001)
Bone
, vol.28
-
-
Dimai, H.P.1
Müller, T.2
Eder, S.3
Hermann, J.4
-
40
-
-
0033197001
-
Genetic determination of variation and covariation of peak bone mass at the hip and spine
-
Deng HW, Stegman MR, Davies KM, Conway T, Recker RR. Genetic determination of variation and covariation of peak bone mass at the hip and spine. Journal of Clinical Densitometry 1999;2:251-63.
-
(1999)
Journal of Clinical Densitometry
, vol.2
, pp. 251-263
-
-
Deng, H.W.1
Stegman, M.R.2
Davies, K.M.3
Conway, T.4
Recker, R.R.5
-
41
-
-
0032835425
-
Vitamin D receptor gene polymorphisms and the risk of fractures in older women
-
For the Study of Osteoporotic Fractures Research Group
-
Ensrud KE, Stone K, Cauley JA, White C, Zmuda JM, Nguyen TV, et al. Vitamin D receptor gene polymorphisms and the risk of fractures in older women. For the Study of Osteoporotic Fractures Research Group. Journal of Bone and Mineral Research 1999;14:1637-45.
-
(1999)
Journal of Bone and Mineral Research
, vol.14
, pp. 1637-1645
-
-
Ensrud, K.E.1
Stone, K.2
Cauley, J.A.3
White, C.4
Zmuda, J.M.5
Nguyen, T.V.6
-
42
-
-
0141997792
-
Association of collagen type 1 (COL1A1) Sp 1 polymorphism with femoral neck bone mineral density and wrist fracture in elderly women
-
forthcoming
-
Gerdhem P, Brändström H, Stiger F, Obrant K, Melhus H, Ljunggren O, et al. Association of collagen type 1 (COL1A1) Sp 1 polymorphism with femoral neck bone mineral density and wrist fracture in elderly women. Calcified Tissue International 2003 (forthcoming).
-
(2003)
Calcified Tissue International
-
-
Gerdhem, P.1
Brändström, H.2
Stiger, F.3
Obrant, K.4
Melhus, H.5
Ljunggren, O.6
|